Thursday, September 24, 2015

Probe - The Ranbaxy–Fortis–Raligare-Radha Swami Beas Quadriangle

So why am I not surprised at the news that Fortis Healthcare Executive Vice Chairman, Shivender Mohan Singh is giving up his role to join the Radha Swami Beas movement in Beas, near Amritsar?

In reports found on this website  it is reported that the present Guru of Radha Swami Beas, Gurinder Singh Dhillon has made $ 254 million and the owner of Logos Holding Company which acquired 19.53% of Raligare Enterprises in 2010.

"The capital market regulator has granted exemption to Logos Holding Company from making an open offer to the shareholders of Religare Enterprises for its acquisition of 19.53% stake in the company. Logos Holding is an investment arm of the Gurinder Singh Dhillon family.
Gurinder Singh is the current head of one of India's largest religious sect – Radha Soami Satsang Beas. At Thursday's closing price of Rs 460.95, the value of Logos Holding's stake is about Rs 1,163 crore. The Dhillons had acquired the shares at just over Rs 13 crore in 2006. - See HERE  

The said share holders of Raligare Enterprises are none other than, the two brothers, Shivender Mohan Singh and his elder brother, Mavinder Mohan Singh.

Singh and older brother Malvinder Mohan Singh, 43, own about 71% of the company. The Singh family's stake in Fortis Healthcare is worth Rs 5,636 crore while its holding in Religare Enterprises is valued at Rs 2,693 crore based on current market cap.”


So now, when the Guru owns 19.53% stake in Raligare Enterprises, it is like coming home to where the business has always been. If Fortis was all about profits, then, going to Beas may not totally be for ‘seva’ only, in the light of the fact that Radha Swami Beas has come up with its own hospital at Beas and is actively urging followers to donate organs after death.

So is there a new business coming up then, for organs to be sold at exorbitant prices, within India and abroad?

The honourable father of the Singh brothers Ranbir Singh, left a legacy of shame, the world of medicine will loathe to forget. Thankfully, Wikipedia comes handy. Sample this:

Issues [faced by Ranbaxy]

During 2004–2005, Dinesh Thakur and Rajinder Kumar, two Indian employees of Ranbaxy, blew the whistle on Ranbaxy's fabrication of drug test reports. Thakur's office computer was soon found tampered with. Ranbaxy then accused Thakur of visiting graphic websites using his office computer, forcing him to resign in 2005. Thakur escaped from India to the USA and contacted the Food and Drug Administration which started investigating his claims.

As a result, on 16 September 2008, the Food and Drug Administration issued two warning letters to Ranbaxy Laboratories Ltd. and an Import Alert for generic drugs produced by two manufacturing plants in India. By 25 February 2009 the US Food and Drug Administration said it halted reviews of all drug applications including data developed at Ranbaxy's Paonta Sahib plant in India because of a practice of falsified data and test results in approved and pending drug applications.

On 8 February 2012, three batches of the proton-pump inhibitor Pantoprazole were recalled in the Netherlands due to the presence of impurities.

On 9 November 2012, Ranbaxy halted production and recalled forty-one lots of atorvastatin due to glass particles being found in some bottles. Also in 2012, an apparent dosage mistake was reported in which 20 mg tablets were found in a bottle of atorvastatin labeled as containing 10 mg tablets; this led in 2014 to the voluntary recall in the United States of some 64,000 bottles.

In May 2013 the US fined the company US$500 million after it was found guilty of misrepresenting clinical generic drug data and selling adulterated drugs to the United States.

In September 2013, further problems were reported, including apparent human hair in a tablet, oil spots on other tablets, toilet facilities without running water, and a failure to instruct employees to wash their hands after using the toilet.[17][18] Ranbaxy is prohibited from manufacturing FDA-regulated drugs at the Mohali facility until the company complies with U.S. drug manufacturing requirements.

Ranbaxy has cleared some regulatory approval hurdles with approval for production at various facilities. Its Gurgaon based plant & Romania R&D centres got FDA approval. Also in March, Ranbaxy's Paonta Sahib plant in Himachal Pradesh, which has faced a US regulatory ban since 2008, was also cleared in a joint inspection by five global drug regulatory agencies of the UK, Canada, the WHO and Singapore. (Credit Wikipedia )


In June 2008, Daiichi-Sankyo acquired a 34.8% stake in Ranbaxy,for a value $2.4 billion. In November 2008, Daiichi-Sankyo completed the takeover of the company from the founding Singh family in a deal worth $4.6 billion by acquiring a 63.92% stake in Ranbaxy. Ranbaxy's Malvinder Singh remained as CEO after the transaction. (Credit Wikipedia )

It is believed that Daiichi-Sankyo were duped and were not aware of the liability they would have to bear in the US market. As soon as they had paid off the liability, they took the best step forward. For Daiichi, Ranbaxy was more of a liability, than a profit making venture. 

"On 7 April 2014 India based Sun Pharmaceutical and Japan based Daiichi Sankyo jointly announced the sale of entire 63.4% share from Daiichi Sankyo to Sun Pharma in a $4 billion all share deal. Under these agreements, shareholders of Ranbaxy, will receive 0.8 share of Sun Pharmaceutical for each share of Ranbaxy. After this acquisition, the partner Daiichi-Sankyo will hold a stake of 9% in Sun Pharmaceutical. The combination of Sun Pharma and Ranbaxy creates the fifth-largest specialty generics company in the world and the largest pharmaceutical company in India.” (Credit Wikipedia )

It certainly is time to move on to the next “seva” venture, Mr Shivender Mohan Singh! Especially, when you come to think of who are the millions of followers who throng the dera in Beas – mostly the poor, the Dalits of Punjab and those who trust Guru Gurinder Singh explicitly.

Read more: HERE

About Radha Swami Beas Hospitals: Click HERE 

Ranbaxy Brothers fined $400 million Click HERE

No comments: